IBDEI0KM ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,9095,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9095,1,3,0)
 ;;=3^Hypersensitivity angiitis
 ;;^UTILITY(U,$J,358.3,9095,1,4,0)
 ;;=4^M31.0
 ;;^UTILITY(U,$J,358.3,9095,2)
 ;;=^60279
 ;;^UTILITY(U,$J,358.3,9096,0)
 ;;=M31.31^^69^618^22
 ;;^UTILITY(U,$J,358.3,9096,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9096,1,3,0)
 ;;=3^Wegener's granulomatosis w/ renal involvement
 ;;^UTILITY(U,$J,358.3,9096,1,4,0)
 ;;=4^M31.31
 ;;^UTILITY(U,$J,358.3,9096,2)
 ;;=^5011745
 ;;^UTILITY(U,$J,358.3,9097,0)
 ;;=N28.89^^69^618^6
 ;;^UTILITY(U,$J,358.3,9097,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9097,1,3,0)
 ;;=3^Kidney & Ureter Disorders,Oth Specified
 ;;^UTILITY(U,$J,358.3,9097,1,4,0)
 ;;=4^N28.89
 ;;^UTILITY(U,$J,358.3,9097,2)
 ;;=^88007
 ;;^UTILITY(U,$J,358.3,9098,0)
 ;;=E85.4^^69^618^11
 ;;^UTILITY(U,$J,358.3,9098,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9098,1,3,0)
 ;;=3^Organ-limited amyloidosis
 ;;^UTILITY(U,$J,358.3,9098,1,4,0)
 ;;=4^E85.4
 ;;^UTILITY(U,$J,358.3,9098,2)
 ;;=^5003017
 ;;^UTILITY(U,$J,358.3,9099,0)
 ;;=M32.14^^69^618^2
 ;;^UTILITY(U,$J,358.3,9099,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9099,1,3,0)
 ;;=3^Glomerular disease in systemic lupus erythematosus
 ;;^UTILITY(U,$J,358.3,9099,1,4,0)
 ;;=4^M32.14
 ;;^UTILITY(U,$J,358.3,9099,2)
 ;;=^5011757
 ;;^UTILITY(U,$J,358.3,9100,0)
 ;;=M32.15^^69^618^15
 ;;^UTILITY(U,$J,358.3,9100,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9100,1,3,0)
 ;;=3^Tubulo-interstitial neuropathy in SLE
 ;;^UTILITY(U,$J,358.3,9100,1,4,0)
 ;;=4^M32.15
 ;;^UTILITY(U,$J,358.3,9100,2)
 ;;=^5011758
 ;;^UTILITY(U,$J,358.3,9101,0)
 ;;=M34.0^^69^618^13
 ;;^UTILITY(U,$J,358.3,9101,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9101,1,3,0)
 ;;=3^Progressive systemic sclerosis
 ;;^UTILITY(U,$J,358.3,9101,1,4,0)
 ;;=4^M34.0
 ;;^UTILITY(U,$J,358.3,9101,2)
 ;;=^5011778
 ;;^UTILITY(U,$J,358.3,9102,0)
 ;;=M31.1^^69^618^14
 ;;^UTILITY(U,$J,358.3,9102,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9102,1,3,0)
 ;;=3^Thrombotic Microangiopathy
 ;;^UTILITY(U,$J,358.3,9102,1,4,0)
 ;;=4^M31.1
 ;;^UTILITY(U,$J,358.3,9102,2)
 ;;=^119061
 ;;^UTILITY(U,$J,358.3,9103,0)
 ;;=E85.81^^69^618^7
 ;;^UTILITY(U,$J,358.3,9103,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9103,1,3,0)
 ;;=3^Light Chain (AL) Amyloidosis
 ;;^UTILITY(U,$J,358.3,9103,1,4,0)
 ;;=4^E85.81
 ;;^UTILITY(U,$J,358.3,9103,2)
 ;;=^5151302
 ;;^UTILITY(U,$J,358.3,9104,0)
 ;;=E85.82^^69^618^23
 ;;^UTILITY(U,$J,358.3,9104,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9104,1,3,0)
 ;;=3^Wild-Type Transthyretin-Related (ATTR) Amyloidosis
 ;;^UTILITY(U,$J,358.3,9104,1,4,0)
 ;;=4^E85.82
 ;;^UTILITY(U,$J,358.3,9104,2)
 ;;=^5151303
 ;;^UTILITY(U,$J,358.3,9105,0)
 ;;=E85.89^^69^618^1
 ;;^UTILITY(U,$J,358.3,9105,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9105,1,3,0)
 ;;=3^Amyloidosis,Other
 ;;^UTILITY(U,$J,358.3,9105,1,4,0)
 ;;=4^E85.89
 ;;^UTILITY(U,$J,358.3,9105,2)
 ;;=^334034
 ;;^UTILITY(U,$J,358.3,9106,0)
 ;;=Z87.442^^69^619^1
 ;;^UTILITY(U,$J,358.3,9106,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9106,1,3,0)
 ;;=3^Personal Hx of Urinary Calculi
 ;;^UTILITY(U,$J,358.3,9106,1,4,0)
 ;;=4^Z87.442
 ;;^UTILITY(U,$J,358.3,9106,2)
 ;;=^5063497
 ;;^UTILITY(U,$J,358.3,9107,0)
 ;;=N20.0^^69^619^2
 ;;^UTILITY(U,$J,358.3,9107,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9107,1,3,0)
 ;;=3^Calculus of Kidney
 ;;^UTILITY(U,$J,358.3,9107,1,4,0)
 ;;=4^N20.0
